Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced new data that are expected to introduce significant, quantifiable time and cost savings into its clinical program for dengue fever.
Island Pharmaceuticals says new data leads to ISLA-101 Phase 2 study changes
June 3, 2024 Australian Biotech
Latest Video
New Stories
-
Alterity Therapeutics updates investors on key meeting with US regulator
March 30, 2026 - - Australian Biotech -
Aroa Biosurgery reports promising trial milestone for advanced wound treatment
March 30, 2026 - - Australian Biotech -
Genetic Signatures reshapes its business to cut costs and drive growth
March 30, 2026 - -
Cynata reaches crucial milestone as Phase 2 trial moves toward results
March 30, 2026 - - Australian Biotech -
AI meets oncology as Algorae advances drug discovery collaboration
March 30, 2026 - - Australian Biotech -
The minister was subtle, but read between the lines, and the message could hardly be clearer
March 30, 2026 - - Latest News -
Government expands access to cancer therapy but holds short on pan-tumour listing
March 30, 2026 - - Latest News
